March 18th 2023
The company also will establish a $35 cap on out-of-pocket costs for Lantus for all patients with commercial insurance.
March 15th 2023
March 14th 2023
Formulary Placement and Outcomes to Drive Physician Use of Humira BiosimilarsFebruary 24th 2023
Bruce Feinberg, D.O., of Cardinal Health, said significantly changes are on the horizon for biosimilars, but physician comfort with and use of biosimilars will depend on things beyond their control, including formulary placement and utilization management efforts.
ICER Gives NASH Drug Resmetirom High Marks, Obeticholic Acid Not So MuchFebruary 20th 2023
At a placeholder price of $19,000, resmetirom would produce cost savings, says the drug evaluation group. Obeticholic acid’s price would need to be slashed to meet a commonly used cost-effectiveness threshold.
Mark Cuban Assails PBMs at AAM meetingFebruary 18th 2023
Cuban, of "Shark Tank' fame and owner of the Dallas Mavericks, called drugs prices ‘insane’ and used some profanity when talking pharmacy benefit managers at the annual meeting of the Association for Accessible Medicines yesterday. Cuban has co-founded an online pharmacy that he says will make drug prices lower and transparent.